• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (5): 682-689.DOI: 10.3969/j.issn.1671-2587.2026.05.003

• 基础研究 • 上一篇    下一篇

介孔硅石负载富血小板血浆促进创面愈合的实验研究*

冯子阳1, 汪非凡1, 陈郑礼2, 屠晓华1, 黄韦华1, 李津杞1, 顾海慧1   

  1. 1海军军医大学第一附属医院输血科,上海 200433;
    2海军军医大学第一附属医院烧伤科,上海 200433
  • 收稿日期:2026-09-02 修回日期:2026-09-23 出版日期:2026-10-20 发布日期:2026-11-11
  • 通讯作者: 顾海慧,主要从事临床输血及细胞治疗与干细胞来源血小板方面研究,(E-mail)haihuigu@126.com。
  • 作者简介:冯子阳,主要从事临床输血治疗工作,(E-mail)ziyangw@126.com。
  • 基金资助:
    *本课题受国家自然科学基金面上项目(No.81970165)、细胞生态海河实验室创新基金(No.HH26KYZX0027)资助

Experimental Study on Mesoporous Silica-Loaded Platelet-Rich Plasma Promoting Wound Healing

FENG Ziyang1, WANG Feifan1, CHEN Zhengli2, TU Xiaohua1, HUANG Weihua1, LI Jinqi1, GU Haihui1   

  1. 1Department of Transfusion Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433;
    2Department of Burns, The First Affiliated Hospital of Naval Medical University, Shanghai 200433
  • Received:2026-09-02 Revised:2026-09-23 Online:2026-10-20 Published:2026-11-11

摘要: 目的 探讨使用介孔硅石(mesoporous silica, MS)负载富血小板血浆(platelet-rich plasma, PRP)的可行性与安全性,对PRP促进创面愈合能力的影响及相关机制。方法 采集大鼠静脉血,经抗凝处理后,采用两步离心法制备PRP。扫描电镜观察MS微观结构,MS通过冷冻干燥法负载PRP,形成PRP@MS,体外实验检测缓释活性及生物相容性。采用随机数表法将30只背部全层皮肤缺损创面的SD大鼠分为常规换药组(生理盐水换药)、PRP组(PRP换药)和PRP@MS组(PRP@MS换药),每组10只大鼠,每4天换药1次。分别在第4天(n=10)、8天(n=10)、12天(n=5)采用像素法计算创面愈合率。在第8天每组随机处死5只大鼠,取创面组织,进行CD31免疫组化、高迁移率族蛋白B1(high-mobility group box 1, HMGB1)免疫组化、Caspase 3免疫组化、沉默信息调节因子3(silent information regulator 3, SIRT3)免疫荧光、诱导型一氧化氮合酶(inducible nitric oxide synthase, iNOS)免疫荧光检测组织学改变。结果 扫描电镜观察到MS具有大量介孔结构,可提供高比表面积。按1∶1负载后,PRP@MS组内VEGF缓释周期>96 h。PRP@MS组无皮内刺激性、无致敏性、无致热性、无急性毒性,生物相容性佳。与常规换药组相比,HE染色、Masson染色和天狼星红苦味酸染色显示可观察到PRP组和PRP@MS组具有更丰富的肉芽组织,胶原蛋白含量更高,且分布更均匀、有序。细胞实验中,与PRP组相比,CCK-8和ELISA结果显示PRP@MS组人皮肤成纤维细胞(human skin fibroblast, HSF)的增殖率及SIRT3的含量显著增加(P<0.05),iNOS的含量明显降低(P<0.05)。动物实验中,与常规换药组及PRP组相比,PRP@MS组在第4、8、12天创面愈合率、创面组织CD31免疫组化阳性细胞数显著升高(P<0.05),创面组织HMGB1免疫组化阳性细胞数显著降低(P<0.05)。与常规换药组相比,PRP@MS组创面组织Caspase 3免疫组化阳性细胞数明显下降(P<0.05),但PRP@MS组与PRP组无显著差异。与常规换药组及PRP组相比,免疫荧光结果显示PRP@MS组SIRT3平均光密度明显升高,iNOS平均光密度明显降低(P<0.05)。结论 PRP@MS具有保护、增效、缓释PRP活性,相较于PRP组具有更高生物活性,且具有良好的生物相容性,综合促进创面愈合,且作用机制与SIRT3上调、iNOS下调相关。

关键词: 介孔硅石, 富血小板血浆, 创面, 沉默信息调节因子3, 诱导型一氧化氮合酶

Abstract: Objective To investigate the feasibility and biosafety of mesoporous silica (MS) loaded with platelet-rich plasma (PRP), as well as its modulatory effect on the wound-healing capacity of PRP and the underlying molecular mechanisms. Methods Venous whole blood was harvested from rats. After anticoagulation, PRP was extracted via a two-step centrifugation protocol. The microstructure of mesoporous silica (MS) was characterized via scanning electron microscopy. PRP was loaded onto MS by freeze-drying method to fabricate PRP@MS composites. Subsequent in vitro experiments were performed to evaluate sustained-release behaviour and biocompatibility. Thirty SD rats with full-thickness dorsal skin wounds were randomly assigned into three groups (n=10 per group) using a random number table ∶ routine dressing group (treated with normal saline), PRP group (treated with PRP), and PRP@MS group (treated with PRP@MS). Dressings were performed every four days. Wound closure rates were quantified by pixel calculation on day 4 (n=10), day 8 (n=10) and day 12 (n=5). On day 8, five rats from each group were euthanised randomly. Wound tissues were harvested for histological detection, including immunohistochemical staining targeting CD31, high-mobility group box 1 (HMGB1) and Caspase 3, alongside immunofluorescence staining of silent information regulator 3 (SIRT3) and inducible nitric oxide synthase (iNOS). Results Scanning electron microscopy revealed abundant mesoporous structures in MS, endowing it with high specific surface area. Following 1∶1 loading ratio, PRP@MS group a sustained VEGF release profile lasting over 96 hours. exhibited sustained vascular endothelial growth factor (VEGF) release profile lasting over 96 hours. The PRP@MS group showed no intradermal irritation, hypersensitivity, pyrogenic reaction or acute toxicity, demonstrating favourable biocompatibility. Compared with the routine dressing group, hematoxylin-eosin (HE), Masson's trichrome and Sirius red-picric acid staining revealed both the PRP and PRP@MS groups had more abundant granulation tissue. higher collagen content, and a more uniform and organized collagen distribution . In cellular experiments, CCK-8 assay and ELISA results illustrated that compared with the PRP group, human skin fibroblast (HSF) cultured with PRP@MS exhibited markedly elevated proliferation activity and intracellular SIRT3 expression, accompanied by decreased iNOS levels (P<0.05). In animal experiments, compared with the routine dressing group and PRP group, the PRP@MS group displayed significantly elevated wound healing rates, counts of CD31 immunohistochemistry positive cells at day 4, 8 and 12 (P<0.05). The number of HMGB1 positive cells were lower in the PRP@MS group (P<0.05). Compared with the routine dressing group, Caspase 3 positive staining was substantially lower in the PRP@MS group (P<0.05), with no statistical difference observed between the PRP and PRP@MS groups. Immunofluorescence results showed that the mean optical density of SIRT3 was significantly increased, while that of iNOS was significantly decreased in the PRP@MS group compared with the other two groups (P<0.05). Conclusion PRP@MS composites can preserve PRP bioactivity, enhance its therapeutic efficacy and achieve sustained factor release. Compared with standalone PRP, PRP@MS exhibits superior biological activity and favourable biocompatibility, thereby facilitating wound healing comprehensively. And the mechanism of action is related to the upregulation of SIRT3 and downregulation of iNOS.

Key words: Mesoporous silica, Platelet rich plasma, Wound, SIRT3, iNOS

中图分类号: